Relapsed childhood acute lymphoblastic leukemia (ALL) carries a poor prognosis, despite intensive retreatment, owing to intrinsic drug resistance 1,2 . The biological pathways that mediate resistance are unknown. Here, we report the transcriptome profiles of matched diagnosis and relapse bone marrow specimens from ten individuals with pediatric B-lymphoblastic leukemia using RNA sequencing. Transcriptome sequencing identified 20 newly acquired, novel nonsynonymous mutations not present at initial diagnosis, with 2 individuals harboring relapse-specific mutations in the same gene, NT5C2, encoding a 5ʹ-nucleotidase. Fullexon sequencing of NT5C2 was completed in 61 further relapse specimens, identifying additional mutations in 5 cases. Enzymatic analysis of mutant proteins showed that base substitutions conferred increased enzymatic activity and resistance to treatment with nucleoside analog therapies. Clinically, all individuals who harbored NT5C2 mutations relapsed early, within 36 months of initial diagnosis (P = 0.03). These results suggest that mutations in NT5C2 are associated with the outgrowth of drug-resistant clones in ALL.
Relapsed childhood acute lymphoblastic leukemia (ALL) carries a poor prognosis, despite intensive retreatment, owing to intrinsic drug resistance 1,2 . The biological pathways that mediate resistance are unknown. Here, we report the transcriptome profiles of matched diagnosis and relapse bone marrow specimens from ten individuals with pediatric B-lymphoblastic leukemia using RNA sequencing. Transcriptome sequencing identified 20 newly acquired, novel nonsynonymous mutations not present at initial diagnosis, with 2 individuals harboring relapse-specific mutations in the same gene, NT5C2, encoding a 5ʹ-nucleotidase. Fullexon sequencing of NT5C2 was completed in 61 further relapse specimens, identifying additional mutations in 5 cases. Enzymatic analysis of mutant proteins showed that base substitutions conferred increased enzymatic activity and resistance to treatment with nucleoside analog therapies. Clinically, all individuals who harbored NT5C2 mutations relapsed early, within 36 months of initial diagnosis (P = 0.03). These results suggest that mutations in NT5C2 are associated with the outgrowth of drug-resistant clones in ALL.
ALL is the most common pediatric malignancy, accounting for more than 25% of all childhood cancers 3 . Cure rates for ALL have substantially improved over the past four decades with the development of riskstratified multiagent chemotherapy, preventive treatment to the central nervous system and the more recent introduction of augmented doses and/or schedules for the administration of conventional drugs, resulting in an overall 5-year event-free survival rate now exceeding 90% (ref. 4) . In spite of these improvements, 10-20% of patients experience disease recurrence 5 . The prognosis for these children is dismal 6 , even with aggressive salvage strategies involving allogeneic stem cell transplantation 7, 8 .
Relapsed ALL remains one of the leading causes of mortality among all childhood malignancies. To discover pathways that mediate the relapse of B-lymphoblastic leukemia (the most common subtype of ALL), we sought to catalog somatic changes enriched at relapse, reasoning that such lesions might be associated with drug resistance and could provide insight into more effective treatment regimens.
Profiling using transcriptome sequencing of specimens from individuals with B-lymphoblastic leukemia ( Supplementary Table 1 ) generated an average of 84 million reads per specimen ( Supplementary  Tables 2 and 3) , and data showed very strong correlation (>90% genotype concordance at >8× coverage) with previously analyzed heterozygous SNP calls from Affymetrix SNP 6.0 arrays of the same specimens ( Supplementary Fig. 1) 9 . Relapse-specific single-nucleotide variants (SNVs) were predicted using the Genome Analysis Toolkit (GATK) 10, 11 ( Supplementary Figs. 2 and 3 ) and subjected to PCR validation by Sanger sequencing of corresponding remission, diagnosis and relapse genomic DNA specimens. We identified 20 missense mutations ( Table 1) that were specifically found in the relapse specimens but were absent from both remission (for example, germline) and diagnosis (leukemia) DNA. Samples from affected individuals each harbored between one and six relapse-specific variants. All of the mutations were hemizygous, with expression also detected for the wild-type allele. In most cases, the mutations were predicted to have a deleterious effect on protein structure that would indicate a dominant-negative mechanism or a state of haploinsufficiency. Nucleotide changes predominantly involved C:G>T:A transitions, resulting in a transition-to-transversion ratio of 1.22 (Supplementary Fig. 4) , similar to the rates described in other studies of human cancer 12 . Although more than half of the mutations were identified in genes recently found to be mutated in cancer genome sequencing projects for head and neck carcinoma, melanoma and ovarian carcinoma [13] [14] [15] [16] , none of the relapse-specific mutations were l e t t e r s the frequency of mutations in NT5C2 in individuals with ALL, full-exon resequencing was completed in an additional 61 relapse specimens. In the 61 affected individuals, 5 further NT5C2 somatic mutations were identified and also validated as relapse specific (Supplementary Fig. 5 ). Thus, 7 out of 71 affected individuals harbored relapse-specific mutations in NT5C2, for an overall occurrence rate of 10% ( Fig. 1a,b) .
Coverage at diagnosis at the two NT5C2 mutated sites identified by RNA sequencing was 96× and 112×. Taking into consideration this depth of sequencing, a subclone at diagnosis would have to be present in less than 1% of the bulk leukemia cells to be missed by this sequencing technique. To assess whether mutations in NT5C2 were present at diagnosis as a rare subclone, backtracking using ultra-deep sequencing was performed. Amplicon resequencing of DNA from diagnosis and relapse specimens identified two cases where a rare clone indeed existed at diagnosis in 0.01% and 0.02% of the total reads (with 25,000× and 32,000× coverage, respectively) ( Table 2 ). In the remaining five cases, no mutation could be detected at diagnosis. These data suggest that the emergence of clones containing mutations in NT5C2 is driven by powerful selective pressures presumably due to drug resistance.
Mutations affecting cN-II were mapped onto the previously published crystal structure 23 . All five mutations found in this study mapped to a single functional unit clustered in a region thought to be involved in subunit association/dissociation through the acidic C-terminal tail of the enzyme ( Fig. 1 and Supplementary Fig. 6 ) 24 . observed in previous targeted sequencing projects focused on pediatric ALL 17, 18 . Genomic DNA sequencing was completed in an additional 62 B-lymphoblastic leukemia diagnosis-relapse specimen pairs to look for further mutations in the affected exon in 9 of the 14 genes associated with cancer genomes (CAND1, CBX3, COBRA1, FBXO3, PRMT2, RGS12, SMEK2, TULP4 and USP7), as well as in 1 newly associated gene, SDF2. However, no additional tumor-specific mutations were found in these exon regions (including shared diagnosis-relapse mutations or relapse-specific mutations). Our inability to detect recurrent relapsespecific mutations in these genes indicates that some of our observed variants might be peripheral to drug resistance (so called passengers) and/or that escape mechanisms might be unique for individual patients, a finding similar to what is observed for metastasis in breast cancer 19 . The remaining genes (DOPEY1, DPH5, LPHN1, MIER3, NEGR1, NIPSNAP1, SCARF1 and ZNF192) were not sequenced further.
Two different mutations were observed and validated in NT5C2, which encodes the protein cN-II, a 5ʹ-nucleotidase enzyme active in the cell cytoplasm 20 , in two of the relapse specimens profiled by RNA sequencing. cN-II, a member of a family of seven enzymes that regulate nucleotide amounts, has been shown to be responsible for the hydrolysis of nucleotides such as 5ʹ-inosine monophosphate and 5ʹ-guanosine monophosphate, converting them into inosine and guanosine nucleosides, respectively 21 . However, this enzyme can also have phosphotransferase activity 20, 22 . Both mutations were confirmed at the DNA level and were specific to the relapse specimens ( Supplementary Fig. 5 ). To determine npg l e t t e r s
We hypothesized that mutations in NT5C2 allow for resistance to chemotherapy treatment, in particular, nucleoside analogs, given their effects on enzymatic function. In addition, the early emergence of NT5C2 mutations correlates with the introduction of the maintenance phase of ALL therapy in which nucleoside analogs assume a predominant role in treatment. Therefore, we investigated whether mutant forms In addition, the focal nature of the observed mutations suggested the acquisition of novel biological properties rather than disruption of enzymatic activity. Therefore, to test the functional impact of the mutations on enzyme activity, we expressed the NT5C2 cDNA for wild-type protein and the Arg238Trp, Arg367Gln and Ser445Phe mutants in BL21 Escherichia coli cells. Protein expression was induced by isopropyl b-D-thiogalactoside (IPTG), and extracts were analyzed for expression by immunoblot ( Fig. 1c) . Equal volumes of fresh protein extracts were then assayed for 5ʹ-nucleotidase activity by monitoring the hydrolysis of inosine monophosphate compared against a standard curve. Significantly higher enzymatic activity was observed for all mutants-Arg238Trp, Arg367Gln and Ser445Phecompared to wild-type protein (P ≤ 0.01; Fig. 1d ). No activity above background was observed with matched non-induced samples. npg l e t t e r s (P = 0.03). Median time to relapse for those with a NT5C2 mutation was 516 d compared to 930 d for those without a NT5C2 mutation (Supplementary Fig. 8 ). Among all individuals that relapsed early, 16% of cases harbored mutations. This finding is consistent with previous data indicating potential differences in the biological pathways that mediate early versus late relapse 9 . These findings provide a detailed look at relapse mechanisms and how sequence alterations can directly result in the chemoresistant phenotypes observed in patients who relapse. In particular, we discovered multiple relapse-specific mutations in NT5C2, a gene not previously associated with somatic mutations in cancer. Our data show a direct relationship between acquired somatic mutations and chemoresistance to a specific class of drugs used in treatment, purine analogs, as opposed to defects in pathways shared across classes of cytotoxic agents. A previous study did not correlate cytosolic 5ʹ-nucleotidase activity with in vitro resistance to 6-thioguanine in blasts from children at diagnosis with ALL, although a weak correlation was seen with the total amount of enzyme 25 . However these studies focused on cases at diagnosis, and, presumably, these cases all contained wild-type NT5C2. In addition, previous studies have correlated high NT5C2 mRNA levels with resistance to cytarabine in patients with acute myeloid leukemia 26, 27 , whereas other studies showed that the purified enzyme does not hydrolyze araC monophosphate 28 . Our results in ALL are in agreement with of cN-II could provide protection from the apoptosis induced by treatment with various chemotherapeutic agents used clinically for childhood ALL. The B-lymphoblastic leukemia cell line Reh was transduced with lentiviruses encoding wild-type or mutant (Arg238Trp, Arg367Gln or Ser445Phe) cN-II and assayed for apoptosis after incubation with various chemotherapeutic agents for 24-72 h (Fig. 2) . Compared to cells expressing wild-type protein, cells expressing mutant forms of cN-II were significantly more resistant to apoptosis after treatment with the purine analogs 6-mercaptopurine and 6-thioguanine ( Fig.  2a,b) . As expected, no resistance was seen when the experiment was repeated with cytarabine, doxorubicin, gemcitabine or prednisolone ( Fig. 2c-f) . To further understand the mechanistic basis of cN-IImediated chemoresistance, we also examined the effects of the NT5C2 mutations on the intracellular accumulation of thiopurine nucleotides, which are active metabolites of 6-mercaptopurine. After treatment with 6-mercaptopurine, Reh cells transduced with lentiviruses expressing mutant forms of cN-II showed reduction in the level of thioguanine nucleotides compared to control cells expressing wild-type protein or GFP (Supplementary Fig. 7) , consistent with the thiopurine resistance resulting from the NT5C2 mutations noted at relapse.
The characteristics of affected individuals with and without NT5C2 mutations were analyzed (Table 3) , and, notably, all individuals who acquired mutations relapsed early, within 36 months of initial diagnosis npg the later finding. We hypothesize that the emergence of clones containing NT5C2 mutations early in maintenance, after completing phases of rotational multiagent chemotherapy, correlates with a greater reliance on these agents. We and others have identified additional genes whose expression might have a role in resistance to purine analogs 29, 30 . However, the discovery of acquired mutations in NT5C2 in individuals with early relapse, a group with a uniformly poor outcome, provides a focal point to develop insight into major biological pathways that mediate drug resistance in vivo and potentially to develop new therapies targeting NT5C2 to prevent the emergence of resistant clones during maintenance therapy and/or to treat relapsed ALL. Inhibitors of 5ʹ-nucleotidase have already been developed, given their potential usefulness in cancer therapy and the prevention of drug resistance to anti-retroviral treatment 31, 32 . Taken together, our data demonstrate that discovery-based approaches can identify recurrent mutations in individuals with cancer who relapse after cytotoxic chemotherapy.
METHODS
Methods and any associated references are available in the online version of the paper.
Targeted validation. Variant validation was completed in eight out of ten discovery specimens for which genomic DNA from matched remission, diagnosis and relapse was available (two samples were not validated owing to unavailable remission genomic DNA). Primers were designed within 400 bp of the variant site, and sequences were amplified by PCR. PCR products were sequenced using Sanger sequencing, and trace files were manually inspected for variation from the reference genome using the Mutation Surveyor program (Softgenetics). All validated mutations were confirmed with a second PCR and Sanger reaction. Full-exon sequencing of NT5C2 (Ensembl transcript ENST00000404739) was completed by Sanger sequencing using exon-specific primers (Genewiz) ( Supplementary Table 4 ).
Roche 454 amplicon sequencing. Targeted amplicon sequencing was performed using the Roche 454 Genome Sequencer FLX+ deepsequencing platform. PCR amplicons spanning the mutated sites were tagged using Roche 454 adaptor-multiplex identifier (MID) tags primer sets and added to PCR primers designed for bidirectional sequencing. Amplicons were then purified with AMPure XP beads (Beckman Coulter) to remove excess primer and quantified by fluorometry using the Quant-iT PicoGreen dsDNA Assay kit. A titration test was performed on the amplicon libraries using a low-volume emulsion PCR amplicon kit according to the Roche 454 protocol, which was followed by emulsion-based clonal amplification (emPCR amplification; Lib-A).
Libraries were sequenced on the Roche 454 Genome Sequencer FLX + sequencing system (454 Life Sciences) at ultra-deep coverage (17,000-50,000×) using a two-region 70-mm × 75-mm Titanium PicoTiterPlate, and mutation analysis was performed using the Roche 454 Amplicon Variant Analyzer package.
Mutation modeling. Molecular representations of cN-II were rendered with ICM-Pro (Molsoft). Molecular surface rendering and exact boundary electrostatic mapping onto that surface were carried out as previously described 39, 40 .
cN-II protein expression and 5ʹ-nucleotidase assay. Full-length
NT5C2 cDNA for wild-type and mutant (Arg238Trp, Arg367Gln and Ser445Phe) (purchased from Genewiz) was cloned into the pET30a expression vector (a gift from J.D. Ernst) using NdeI and HindIII restriction sites. pET30a expression vectors were transformed into BL21 DE3 pLysS chemically competent E. coli (Invitrogen). NT5C2 expression was induced using 1 mM IPTG with 5 h of incubation at 37 °C. Cells were pelleted at 8,000g for 2 min at 4 °C and resuspended in lysis buffer (50 mM NaH 2 PO 4 , 300 mM NaCl and 10 mM imidazole) with 1× protease inhibitors (GE Healthcare). Then, 1 mg/ml lysozyme was added, and samples were incubated on ice for 30 min. Lysates were centrifuged at 15,000g for 10 min at 4 °C. Protein was subjected to electrophoresis on 9% SDS-Tris acrylamide gels and transferred to PVDF membranes. Membranes were incubated with a 1:5,000 dilution of rabbit polyclonal antibody to cN-II (ab96084, Abcam), incubated with a 1:10,000 dilution of horseradish peroxidase (HRP)-conjugated secondary antibody to rabbit (GE Healthcare) and developed using enhanced chemiluminescence (ECL; GE Healthcare). Purified protein extract (10 ml) was used to assess the enzymatic activity of wild-type and mutant proteins using the 5ʹ-Nucleotidase Enzymatic Test kit (Diazyme) according to the provided protocol. Data are represented as the mean ± s.d. from three independent experiments.
Cell culture and drug treatment. Reh cells obtained from the American Type Culture Collection (ATCC) were grown in RPMI1640 supplemented with 10% FBS, 10 mM HEPES and 1% penicillin-streptomycin
ONLINE METHODS
Specimens. Cryopreserved matched pairs of pediatric B-lymphoblastic leukemia marrow specimens from diagnosis and relapse and, when available, remission were obtained from the Children's Oncology Group (COG) ALL cell bank from ten affected individuals ( Supplementary  Table 1 ) from trials AALL0232, AALL0331 and COG 9906 (NCT00075725, NCT00103285 and NCT00005603 at ClinicalTrials.gov, respectively). All specimens were Ficoll enriched before cryopreservation and contained >80% blasts, as measured by flow cytometry before enrichment. All subjects (or their parents) provided written consent for banking and future research use of these specimens in accordance with the regulations of the institutional review boards of all participating institutions. Time to relapse was calculated from the initial diagnosis date. Samples were chosen on the basis of bone marrow blast percentage at the time of bank submission, as well as by Affymetrix SNP 6.0 chip data. All samples with less than 20% disparity between the two methods and with >80% blasts in both diagnosis and relapse samples were considered for sequencing. RNA was extracted from diagnosis and relapse bone marrow samples using RNeasy Mini kits (Qiagen), and quality was verified with an Agilent Bioanalyzer 2100 (Agilent Technologies).
RNA sequencing and analysis. Libraries were prepared according to the standard protocol for sequencing using the Illumina Genome Analyzer IIx. Final cDNA libraries were evaluated for fragment size distribution by Agilent Bioanalyzer 2100 (DNA 1000 chip) and quantified by Quanti-iT PicoGreen dsDNA Assay kit (Invitrogen). All libraries were sequenced using 54-bp reads on the Illumina Genome Analyzer IIx. Image collection and analysis were completed using the Illumina CASAVA pipeline. Reads in raw FASTQ files were aligned to the human reference genome (hg18) using the Burroughs-Wheeler Aligner (v0.5.8a) 34 , allowing up to two mismatches. Data are deposited at the NCBI Sequence Read Archive (SRA048657). Mapped reads in the raw BAM files were then recalibrated and locally realigned to call SNVs and insertions and/or deletions (indels) using GATK 10 . After removing duplicate reads, only those reads with mapping quality Q of ≥30 were used to predict SNVs and indels, again using GATK 11 .
Data were subjected to a set of post-processing filters requiring (i) a minimum of 8× coverage per variant site; (ii) reads supporting the variant in >20% of the total reads per site; (iii) bidirectional sequence support of variant reads; (iv) no more than one variant within a 5-bp window; and (v) a minimum of 8× wild-type coverage at the corresponding site in the paired diagnosis sample. Variants were filtered for known SNPs from the most current dbSNP database, dbSNP 135, and 1000 Genomes Project data 35 . Finally, only those variants present in genes with the most conservative annotation by RefSeq were considered (all XM annotations were removed). All predicted variants were then manually inspected on the paired BAM files using the Integrative Genomics Viewer (IGV) 36 . Predicted SNVs were compared to the COSMIC v55 database 14 and processed using the PolyPhen-2 prediction program and SIFT 37, 38 . A schematic of the filtering process for SNV detection is provided in Supplementary Figure 2 . A schematic for indel detection is provided in Supplementary Figure 3. Fusion detection. Paired-end data (n = 4 pairs) were processed using an in-house pipeline BEGAT (C.E.M., unpublished data). Results were filtered to remove candidates that (i) were covered by fewer than eight reads; (ii) were in a region less than 10 kb away from each other; (iii) represented mapping errors between gene isoforms and paralogs, as determined with a homologous gene filter; and (iv) were fusions that mapped to repetitive regions (Supplementary Note). npg under 5% CO 2 at 37 °C. 293T cells (ATCC) were grown in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin under 5% CO 2 at 37 °C. 6-mercaptopurine, 6-thioguanine, cytarabine, doxorubicin, gemcitabine and prednisolone (Sigma) were serially diluted in RPMI before use at the indicated concentrations.
Transient transfection and lentivirus gene transfer. NT5C2 cDNA for wild-type and mutant (Arg238Trp, Arg367Gln and Ser445Phe) was cloned into the lentiviral vector pLenti (a gift from M.R. Phillips) using SalI and XbaI restriction sites. All plasmids were sequence verified. cDNA constructs were transfected into 293T cells along with helper plasmids using the calcium phosphate method to produce replication-defective virus. Supernatant was harvested 48 h later and used to transduce Reh cells (whose NT5C2 sequence was verified as wild type) supplemented with 8 mg/ml polybrene (Sigma). Virus-containing medium was replaced 24 h after infection. Cells were monitored 72 h after infection for infection efficiency by the detection of GFP-positive cells using a FACScan (BD). We plated 200,000 infected cells per well in 200 ml of medium in triplicate for drug treatment with 6-mercaptopurine, 6-thioguanine, cytarabine, doxorubicin, gemcitabine and prednisolone (Sigma). Cells were incubated for 24-72 h and then assayed for apoptosis by Annexin V-PE and 7-AAD staining (Annexin V-PE Apoptosis Detection kit, BD Pharmingen) followed by flow cytometry analysis using a FACScan. The percentages of cells positive and negative for Annexin V and/or 7-AAD staining were analyzed with FlowJo software (version 7.6.1, Tree Star). Data were plotted relative to results obtained with no chemotherapy treatment, and error bars represent the standard deviation from three independent determinations. We harvested 1 ×10 6 cells for protein at the time of plating. Briefly, cells were pelleted at 200g for 5 min and resuspended in 100 ml of RIPA buffer with 1× protease inhibitors (GE Healthcare), incubated on ice for 15 min and centrifuged at 15,000g for 10 min at 4 °C. Protein was subjected to electrophoresis on 9% SDS-Tris acrylamide gels and transferred to PVDF membranes.
Membranes were incubated with a 1:5,000 dilution of antibody to Flag (F3165, Sigma), incubated with a 1:10,000 dilution of HRP-conjugated secondary antibody to mouse (GE Healthcare) and developed using ECL (GE Healthcare).
HPLC determination of nucleotides. Reh cells were transiently infected with NT5C2 constructs. After infection, cells were treated with 10 mM 6-mercaptopurine for 24 h in duplicate. After 24 h, 5 × 10 6 cells were washed twice with PBS, and cells pellets were frozen at -80 °C. Intraceullar accumulation of thioguanine nucleotides (6-mercaptopurine active metabolites) was determined by a reversed-phase liquid chromatography assay as described previously 41 .
Statistical analysis. Statistical analysis of enzymatic and chemoresistance assays was performed using the two-sided unpaired Student's t test. Statistical analysis of the clinical and biological characteristics of study subjects with NT5C2 mutations was performed using Fisher's exact test. P < 0.05 was considered to be statistically significant.
